Integral Diagnostics Limited Overview
Integral Diagnostics is an Australasian diagnostic imaging services group operating 142 clinics (62 of them "comprehensive" full-modality sites) across Victoria, Queensland, Western Australia, Tasmania, South Australia and New Zealand, supported by 468 reporting radiologists and a fast-growing teleradiology arm, IDXt. Following its December 2024 scrip merger with Capitol Health, IDX describes itself as having the second-largest clinic network in Australia, with roughly a 12% share of the national diagnostic imaging market and around 19% in its key operating states. Revenue is overwhelmingly derived from fee-for-service imaging reimbursed by Medicare plus patient gap fees, supplemented by hospital reporting contracts and teleradiology. Its differentiating claim is a "medical leadership model" that embeds radiologists in governance, including a radiologist on the board. In FY26 it generated A$788.7m of revenue, A$164.8m of operating EBITDA (20.9% margin) and A$47.4m of operating NPAT, and is now in a leadership transition under new CEO Jason Martinez.
Company's own description (FY26 Annual Report, paraphrased)
IDX describes itself as a leading provider of medical diagnostic imaging services in Australia and New Zealand that uses non-invasive imaging technologies to create images of bones, tissues and organs to diagnose and treat illness and injury. Its modalities are MRI, nuclear medicine (including PET), CT, mammography, ultrasound and radiography (X-ray and EOS). It serves referrers — general practitioners, dental practitioners, medical specialists and allied health professionals — and their patients. Comprehensive sites offer the full modality range and are generally located with or near major specialist referrers who require higher-complexity imaging. Its stated vision is "a healthier world" and its purpose is to deliver the best health outcomes for patients; its corporate tagline is that good medicine is good business.
Independent characterisation
IDX is a capital-intensive, labour-intensive, reimbursement-driven healthcare services business. The economic engine is: (1) referral capture from GPs and specialists; (2) conversion of referrals into imaging examinations on owned equipment; (3) radiologist reporting; and (4) billing to Medicare (bulk-billed) or Medicare plus a patient out-of-pocket gap. Three structural profit levers dominate:
-
Modality mix. CT, MRI and PET carry far higher fees per exam than X-ray and ultrasound. IDX's average fee per exam in Australia rose 6.5% in FY26 against Medicare indexation of only 2.4%, the difference being mix shift toward higher-end modalities (FY26 Annual Report).
-
Radiologist productivity. Radiologists are the scarcest and most expensive input. Teleradiology (IDXt, ~15% of scans) and AI tools (~10% of scans) are deployed to raise reports per radiologist (FY26 Annual Report, Industry and Regulatory Outlook).
-
Fixed-cost leverage. Rent, equipment and staffed rosters are largely fixed; incremental volume through existing sites expands margin. Group operating EBITDA margin moved from 19.3% (FY23) to 20.9% (FY26).
Revenue model mix
| Revenue stream | Description | Disclosure status |
|---|---|---|
| Fee-for-service imaging (Medicare + patient gap) | Core revenue; Medicare Benefits Schedule rebates plus out-of-pocket fees; bulk billing for some patients | Dominant; exact % not publicly disclosed |
| Reporting contracts | Fixed-rate or per-report contracts with hospitals (public and private) | Included in "average fees per exam (including reporting contracts)"; separate revenue not disclosed |
| Teleradiology (IDXt) | Urgent, routine and overflow reporting for IDX, private practices and public hospitals across all Australian states and NZ | Revenue not separately disclosed; reported ~15% of IDX Australian revenue at FY24 (FY24 Results release); reporting volumes up >30% in FY26 |
| National Lung Cancer Screening Program (NLCSP) | Government-funded low-dose CT screening from 1 Jul 2025 | ~14% national share of screens in FY26; revenue not disclosed |
| New Zealand private and publicly outsourced imaging | Private insurance, ACC, self-pay and public outsourcing (NZ has no Medicare equivalent) | NZ revenue not separately quantified in sources reviewed |
There is no product, subscription or licensing revenue of significance; IDX is a pure services business.
Value-chain position
IDX sits in the provider layer: it buys equipment (from global OEMs such as Siemens Healthineers, GE HealthCare, Philips, Canon — specific supplier contracts not disclosed), leases premises (right-of-use assets A$228.5m at 30 Jun 2026), employs clinical staff, and bills payers. It does not manufacture equipment or develop software at scale.
Customers and end-markets
| Customer / referrer type | Role |
|---|---|
| General practitioners | Largest referral base, especially legacy Capitol (Melbourne metro community imaging); sensitive to GP attendance trends |
| Medical specialists (orthopaedic, oncology, cardiology, neurology, breast) | Drive high-acuity CT/MRI/PET volumes at comprehensive sites |
| Dental practitioners | OPG/cone-beam dental imaging |
| Allied health (physiotherapists etc.) | Musculoskeletal imaging |
| Hospitals (public and private) | Reporting contracts, co-located practices (e.g., Eastwood Private Hospital, Maroochy Private Hospital) |
| Elite sport | Imaging @ Olympic Park (Melbourne) musculoskeletal centre of excellence |
| Patients | 1.757m patients seen in FY26; 4.099m exams |
| Referrer count | >70,000 referrers in FY26 |
Strategy
Stated strategy (FY26 Annual Report, themes)
| Strategic priority | Theme | Initiatives |
|---|---|---|
| Core Growth & Optimisation | Execute within the platform | Organic volume growth; modality mix optimisation; operating productivity; margin improvement; referrer and patient growth |
| Network Expansion | Disciplined, selective growth | MRI deregulation opportunities; greenfields; brownfield expansion; hospitals and partnerships; scale IDXt; disciplined capital allocation |
| People & Culture | Capacity, capability and culture | Radiologist attraction and retention; One IDX culture; leadership capability; engagement, safety and wellbeing |
| Transformation & Innovation | Better pathways and productivity | Patient and referrer experience; digital pathway transformation; AI and technology enablement; data and workflow optimisation; adjacent growth |
Vision: a healthier world. Purpose: deliver the best health outcomes for patients.
Values: patients first; medical leadership; one team; create value; integrity and excellence; embrace change.
Targeted outcomes: sustainable revenue growth; operating EBITDA margin >21.0%; increased productivity and capacity; improved patient access; de-gearing.
New CEO's agenda (Martinez letter, Aug 2026)
-
A 90-day clinic-by-clinic review of business, clinical, technology and cultural foundations (running roughly August to early November 2026).
-
Three initial focus areas: (1) operating margin — income-stream optimisation, labour cost management, radiologist productivity via technology, capex discipline; (2) clinician recruitment and retention; (3) culture and values.
-
Development of an updated strategic plan with the board, underpinned by a technology roadmap, explicitly targeting the July 2027 full MRI deregulation opportunity using IDX's scale.
Initiatives in the last 24 months
| Initiative | Status / metric | Source |
|---|---|---|
| Capitol Health merger integration | "Largely complete"; synergies A$14.0m+ vs ≥A$10m original target | FY26 Results |
| Group procurement function | Savings ahead of plan; further procurement efficiencies targeted in FY27 | FY26 Annual Report |
| IDXt scale-up | 80 contracted radiologists (Aug 2024) → 114 (Jun 2025) → 124 (Dec 2025) → 143 (Jun 2026) | FY24, FY26 releases |
| MRI licence expansion | 23 → 42 licensed MRIs in Australia from Jul 2025 | FY26 Annual Report |
| NLCSP participation | ~14% national share; ~21% in key states | FY26 Annual Report |
| Orthopaedic hospital practices | Eastwood (SA) and Maroochy (Qld) | FY26 Annual Report |
| Greenfields | Wangaratta, Launceston relocation, Armstrong Creek (under construction) | FY26 Annual Report |
| Workforce programs | Registrar engagement, International Medical Graduate development, in-house sonographer/radiographer training | FY26 Annual Report |
| System consolidation | Ongoing; delayed 2026 engagement survey to Nov 2026 | FY26 Annual Report |
| AI governance framework | Risk-tiered assessment of AI use cases | FY26 Annual Report |
| DEI Strategy 2026–2028; first Reconciliation Action Plan due FY27 | In progress | FY26 Annual Report |
| Debt hedging | 51.2% of gross debt hedged from late Dec 2025 | FY26 Annual Report |
| NZ strategic review | Reported in secondary source only (unconfirmed) | Quartr summary |
Guidance and medium-term targets
| Item | Guidance | Source |
|---|---|---|
| FY27 replacement + growth capex | A$50.0m–A$60.0m | FY26 Results |
| Operating EBITDA margin | Improve to >21.0% (no date specified) | FY26 Results |
| Leverage | Target range 2.0x–2.5x net debt/EBITDA, trending down | FY26 Annual Report |
| Dividend payout | 73% of operating NPAT in FY26 (no formal policy range extracted) | FY26 Annual Report |
| FY27 revenue / earnings | No numerical guidance issued | — |
Products & Services
IDX sells services, not products; the "catalog" is a set of imaging modalities, sub-specialty services and service channels. Prices are set by the Medicare Benefits Schedule (MBS) rebate plus any out-of-pocket gap the practice charges; IDX does not publish a price list.
Imaging modalities
| Service | Description / capability | Target referrer / patient | Pricing model | Notes |
|---|---|---|---|---|
| MRI (incl. 3T) | Soft-tissue, neuro, MSK, prostate, cardiac MRI | Specialists; GPs for eligible items | MBS rebate (licence-dependent until full deregulation) + gap | 42 licensed MRIs in Australia from Jul 2025 (vs 23); full deregulation 1 Jul 2027 |
| CT | Diagnostic CT incl. low-dose lung screening CT | GPs, specialists, NLCSP | MBS + gap; NLCSP items | ~14% national NLCSP share in FY26 |
| PET-CT / Nuclear medicine | Oncology staging, cardiac, neuro | Oncologists, specialists | MBS; PET excluded from FY26 2.4% indexation | PET growth expected from NLCSP follow-ups; PET-CT greenfield at Noosa (Qld) and Cavendish (NZ) |
| Mammography | Screening and diagnostic breast imaging | GPs, breast surgeons | MBS + gap | Women's Imaging (Tas); breast sub-specialty in Vic Regional and NZ |
| Ultrasound | General, obstetric, gynaecological, vascular, MSK | GPs, obstetricians | MBS + gap | NZ business is the country's largest obstetric scan provider |
| X-ray (low-dose digital) | General radiography | GPs, allied health | MBS, often bulk billed | High-volume, low-fee |
| EOS imaging | Low-dose full-body standing skeletal imaging | Orthopaedic and spinal specialists | MBS | Listed in company modality list |
| Bone densitometry (DEXA) | Osteoporosis assessment | GPs | MBS | Per company description (secondary source ROIC.ai) |
| Dental imaging (OPG, cone beam CT) | Dental and maxillofacial | Dentists | MBS/private | Per company description (secondary source) |
| Echocardiography | Cardiac ultrasound | Cardiologists | MBS | Per company description (secondary source) |
| Interventional radiology | Image-guided procedures, biopsies, injections, pain management | Specialists | MBS + gap | Imaging @ Olympic Park integrates day procedures |
Sub-specialty clinical services
| Sub-specialty | Where concentrated |
|---|---|
| Musculoskeletal / sports imaging | Imaging @ Olympic Park; Fowler Simmons (SA); orthopaedic hospital practices (Eastwood, Maroochy) |
| Neuroradiology | New Zealand, Victoria Regional |
| Oncology imaging | Victoria Regional, NZ, PET sites |
| Women's health (obstetric, gynaecological, breast) | Women's Imaging (Tas), NZ |
| Cardiac imaging | Victoria Regional |
| Lung cancer screening | Group-wide, under NLCSP |
Service platforms
| Platform | Description | Launch | Scale (latest) |
|---|---|---|---|
| IDXt teleradiology | Urgent, routine and overflow reporting across all modalities for IDX, private practices and public hospitals | 2,020 | 143 teleradiologists (30 Jun 2026); reporting volumes up >30% vs FY25; ~15% of group scans |
| AI-assisted reporting | AI tools used in ~10% of scans under a structured AI governance framework | — | ~10% of scans |
| Comprehensive hospital-based practices | Integrated orthopaedic imaging inside specialist hospitals | FY26 | Eastwood Private Hospital (SA, opened FY26); Maroochy Private Hospital (Qld, now open) |
Brand register
| Brand | Region | Origin |
|---|---|---|
| Lake Imaging | Vic Regional | Legacy IDX |
| The X-Ray Group | Vic Regional | Legacy Capitol (per business unit listing) |
| Capital Radiology | Vic Metro | Legacy Capitol |
| FMIG | Vic Metro | Legacy Capitol |
| Imaging @ Olympic Park | Vic Metro | Legacy Capitol |
| Imaging Queensland | Qld | Legacy IDX (acquisition; earn-out outstanding) |
| South Coast Radiology | Qld | Legacy IDX |
| Apex Radiology | WA | Legacy IDX |
| Radiology Tasmania | Tas | Legacy Capitol |
| Women's Imaging | Tas | Legacy Capitol |
| Fowler Simmons Radiology | SA | Legacy Capitol |
| Astra Radiology | NZ | Legacy IDX (third-party data lists "Ascot Radiology"; possible rebrand) |
| Trinity MRI | NZ | Legacy IDX |
| SRG Radiology | NZ | Legacy IDX |
| Horizon Radiology | NZ | Legacy IDX (FY23 acquisition) |
| IDXt | ANZ | Internal start-up (2020) |
Financial Narrative
Income statement: notes and sources
Sources: FY22 Annual Report (FY22 operating revenue); FY24 Results release (FY23–FY24); FY26 Annual Report (FY25 restated, FY26). FY22 dividend derived: FY23 dividend of 6.0c was reported as down 14% on FY22 (FNArena) and FY22 final was 3.0c (FY22 Appendix 4E), consistent with a 7.0c total. Gross profit is not reported — IDX presents expenses by nature (employee, consumables, occupancy etc.), so gross profit is "not publicly disclosed".
Margins
FY23–FY24 EBITA and NPAT margins derived; FY25–FY26 operating NPAT margin and payout from FY26 Annual Report.
Growth
FY23 revenue growth derived from 358.7 → 440.8 (FNArena reported ~22% using rounded figures). Revenue CAGR FY22–FY26: ~21.8% (derived; FY22 base is "operating revenue"). Revenue CAGR FY23–FY26: ~21.4% (derived). The CAGR is overwhelmingly acquisition-driven; Australian organic growth has run at ~7–9% per annum.
Commentary. The five-year record has three distinct phases. FY22–FY23 was a COVID and cost-inflation trough: FY22 revenue grew only 2.8% and operating EPS almost halved, and Jarden noted EBITDA margins fell every half for two years to an 18.5% nadir in 1H FY23. FY24 was a stabilisation year marred by the A$71.6m New Zealand impairment, which swung statutory NPAT to a A$60.7m loss even as operating EBITDA margin edged up to 19.5% and a strong 2H (20.3% margin) set up recovery. FY25–FY26 is the merger phase: Capitol added ~A$127m of revenue in FY25 (part-year) and the full-year effect drove FY26 revenue to A$788.7m, while A$14m+ of synergies and fixed-cost leverage lifted operating EBITDA margin 160 bps across two years. The persistent gap between operating and statutory profit (A$25.4m in FY26) reflects integration, restructuring and amortisation; the board expects the gap to narrow significantly beyond FY26. EPS growth (23.6% in FY26) lags NPAT growth (50.1%) because the share count rose ~60% with the merger scrip.
Balance sheet
Sources: FY24 Results release; FY26 Annual Report (FY25 restated). Net debt includes A$6.5m of bank guarantees and excludes A$1.9m capitalised borrowing costs (FY26). Current borrowings shown as nil because no current borrowings line appears in the FY26 summary balance sheet. FY25 working capital derived from FY26 movement disclosure (increase of A$1.3m to −A$66.0m). Net tangible assets per share were negative (−105.56c at 30 Jun 2026; units as reported in Appendix 4E), reflecting goodwill-heavy acquisition accounting.
Commentary. The merger doubled equity (A$301.7m → A$692.0m) via scrip while net debt rose ~A$115m as Capitol's debt was refinanced into the group facility. Intangibles now represent ~59% of total assets (A$846.8m / A$1,427.4m), so book value is dominated by goodwill and brands; tangible equity is negative. The balance sheet is nonetheless serviceable: 2.3x covenant leverage, A$117m undrawn committed headroom, a further A$200m uncommitted, and a facility tenor to December 2029. Negative working capital (−A$66m) is structural — patients pay at or near point of service while staff and suppliers are paid in arrears.
Cash flow
Sources: FY24 Results release; FY26 Annual Report cash flow summary; FY25 statutory operating cash flow from FNArena (secondary). Company "operating free cash flow" = operating EBITDA ± non-cash items ± working capital − lease principal − replacement capex (pre-tax, pre-interest, pre-growth capex). No buyback has been announced in the period reviewed. Transaction and integration costs paid derived: FY25 20.6 + 11.3; FY26 3.3 + 16.3.
Commentary. Company-defined free cash flow nearly doubled from A$53.1m (FY23) to A$106.4m (FY26), tracking EBITDA. After tax, interest, growth capex, dividends and A$19.6m of integration cash costs, FY26 net cash flow was roughly break-even (+A$0.4m), which is why net debt was flat despite strong operating cash generation. As integration costs fade in FY27, the same operating cash flow should translate into genuine de-gearing — the key test of the "de-gearing" outcome in IDX's strategy.
Ratios
FY25 and FY26 net debt/equity reported; FY23–FY24 derived. ROE, ROA, asset turnover, interest cover and receivable days derived by this analyst from disclosed figures. Cash conversion cycle is not meaningful for a services business with minimal inventory and is not disclosed; receivable days (~14) indicates fast collection. Covenant leverage uses pre-AASB 16 LTM EBITDA of A$129.6m (FY26) and A$116.4m (FY25).
Commentary. Returns remain modest. A 7.6% ROIC on operating EBIT is likely below or near the company's weighted average cost of capital, which is the central bear point on the merger: the deal created scale and synergies, but goodwill-heavy capital has not yet produced compelling returns. The positive is the direction of travel — ROIC, margin and interest cover all improved in FY26, and interest cost fell almost 90 bps with 51.2% of gross debt hedged from late December 2025.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment
| Metric (AUD Mn) | FY24 | FY25 | FY26 |
|---|---|---|---|
Legacy IDX revenue | 469.7 | 501.2 | — |
Legacy Capitol revenue (from 20 Dec 2024) | 0 | 126.8 | — |
Consolidated revenue and other income | 469.7 | 628.0 | 788.7 |
Legacy IDX operating NPAT | 18.1 | 19.6 | — |
Legacy Capitol operating NPAT | 0 | 12.0 | — |
Consolidated operating NPAT | 18.1 | 31.6 | 47.4 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue by Segment (%) and Segment Margins & Growth (%)
| Metric (%) | FY24 | FY25 | FY26 |
|---|---|---|---|
Legacy IDX revenue contribution | 100 | 79.8 | — |
Legacy Capitol revenue contribution | 0 | 20.2 | — |
Legacy IDX Australian organic revenue growth | 7.2 | 7.3 | 8.9 |
Legacy Capitol organic revenue growth | — | 5.2 | 5.4 |
Revenue by Segment and Segment Margins & Growth (%)
| Metric (AUD Mn) | 1H FY25 | 2H FY25 | 1H FY26 | 2H FY26 |
|---|---|---|---|---|
Revenue and other income | 252.9 | 375.1 | 393.5 | 395.2 |
Operating EBITDA | — | — | 81.1 | 83.7 |
Operating EBITDA margin (%) | — | — | 20.6 | 21.2 |
Business Units
| Business unit | Key brands | Total clinics | Comprehensive clinics | Strategic role |
|---|---|---|---|---|
Victoria – Metro | Capital Radiology, FMIG | 45 | 23 | Community imaging, large GP base, rising specialist mix |
Victoria – Regional | Lake Imaging, The X-Ray Group | 17 | 7 | Hospital and community imaging in western Victoria; MSK, oncology, cardiology, breast |
Victoria – IOP | Imaging @ Olympic Park | 1 | 1 | National MSK centre of excellence; elite sport; integrated imaging and day procedure centre |
Queensland | Imaging Queensland, South Coast Radiology | 40 | 17 | Gold Coast, Sunshine Coast, Brisbane, Central Qld |
Western Australia | Apex Radiology | 12 | 4 | Largest regional diagnostic service in WA; small but growing Perth presence |
Tasmania | Radiology Tasmania, Women's Imaging | 5 | 3 | State's leading community imaging provider |
South Australia | Fowler Simmons Radiology | 2 | 2 | MSK centre of excellence; Eastwood Private Hospital clinic |
New Zealand | Astra Radiology, Trinity MRI, SRG Radiology, Horizon Radiology | 19 | 5 | Greater Auckland; neuro, MSK, oncology, breast; largest obstetric scan provider in NZ |
Teleradiology | IDXt | — | — | 143 reporting radiologists (114 at 30 Jun 2025) |
Total | — | 141 listed (142 reported) | 62 | — |
Income Statement and Per-Share Data
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
Revenue and other income (AUD Mn) | 358.7 | 440.8 | 469.7 | 628.0 | 788.7 |
Operating EBITDA (AUD Mn) | — | 85.2 | 91.5 | 126.5 | 164.8 |
Operating EBITA (AUD Mn) | — | 43.8 | 46.1 | 70.0 | 97.1 |
Operating NPAT (AUD Mn) | — | 17.9 | 18.1 | 31.6 | 47.4 |
Statutory NPAT (AUD Mn) | — | 25.0 | -60.7 | 2.8 | 22.0 |
Operating diluted EPS (AUD cents) | — | 7.6 | 7.7 | 10.2 | 12.6 |
Statutory basic EPS (AUD cents) | — | — | — | 0.9 | 5.9 |
Statutory diluted EPS (AUD cents) | — | — | — | 0.9 | 5.8 |
Dividends declared per share (AUD cents) | 7.0 | 6.0 | 5.8 | 6.5 | 9.3 |
Margin Analysis (%)
| Metric (%) | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
Operating EBITDA margin | 19.3 | 19.5 | 20.1 | 20.9 |
Operating EBITA margin | 9.9 | 9.8 | 11.1 | 12.3 |
Operating NPAT margin | 4.1 | 3.9 | 5.0 | 6.0 |
Statutory net margin | 5.7 | -12.9 | 0.4 | 2.8 |
Dividend payout on operating NPAT | — | 74.4 | 76.3 | 73.0 |
Margin Analysis (%) (FY22–FY26)
| Metric (%) | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
Revenue growth YoY | 2.8 | 22.9 | 6.6 | 33.7 | 25.6 |
Operating EBITDA growth YoY | — | — | 7.4 | 38.3 | 30.3 |
Operating NPAT growth YoY | — | — | 1.3 | 77.4 | 50.1 |
Operating diluted EPS growth YoY | -46.2 | — | 1.0 | 32.9 | 23.6 |
Balance Sheet
| Metric | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
Total assets (AUD Mn) | — | — | 1,424.6 | 1,427.4 |
Cash and equivalents (AUD Mn) | — | 42.4 | 52.1 | 51.3 |
Borrowings – non-current (AUD Mn) | — | — | 341.3 | 341.8 |
Borrowings – current (AUD Mn) | — | — | 0 | 0 |
Lease liabilities – current (AUD Mn) | — | — | 20.3 | 21.5 |
Lease liabilities – non-current (AUD Mn) | — | — | 223.4 | 233.9 |
Net debt pre-AASB 16 (AUD Mn) | 194.5 | 183.5 | 298.0 | 298.9 |
Total equity (AUD Mn) | 373.0 | 301.7 | 692.0 | 681.5 |
Intangible assets incl. goodwill (AUD Mn) | — | — | 861.7 | 846.8 |
Property, plant and equipment (AUD Mn) | — | — | 243.0 | 248.5 |
Right-of-use assets (AUD Mn) | — | — | 224.6 | 228.5 |
Total current assets (AUD Mn) | — | — | 95.3 | 99.4 |
Total current liabilities (AUD Mn) | — | — | 142.0 | 148.6 |
Working capital as reported (AUD Mn) | — | — | -64.7 | -66.0 |
Committed debt facilities (AUD Mn) | — | 353.7 | — | 467.4 |
Undrawn committed facilities (AUD Mn) | — | 128.5 | — | 117.0 |
Cash Flow and Margin Analysis (%)
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
Statutory net operating cash flow (AUD Mn) | — | — | — | 73.8 | — |
Operating free cash flow – company definition (AUD Mn) | — | 53.1 | 56.0 | 81.4 | 106.4 |
Replacement capex (AUD Mn) | — | — | — | 28.0 | 28.8 |
Growth capex (AUD Mn) | — | — | 9.3 | 27.3 | 21.0 |
Total capex (AUD Mn) | — | — | 23.9 | 55.3 | 49.8 |
Lease principal payments (AUD Mn) | — | — | — | 18.4 | 20.7 |
Tax paid (AUD Mn) | — | — | — | 4.0 | 13.7 |
Interest and borrowing costs paid incl. leases (AUD Mn) | — | — | — | 29.6 | 27.6 |
Dividends paid – cash (AUD Mn) | — | — | — | 15.5 | 25.8 |
Dividends paid incl. DRP (AUD Mn) | — | — | 13.8 | 16.8 | 27.0 |
Transaction and integration costs paid (AUD Mn) | — | — | — | 31.9 | 19.6 |
Share buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
FCF conversion before replacement capex (%) | — | 92.9 | 77.2 | 86.5 | 82.0 |
Financial Ratios (x) and Returns & Leverage Ratios (%)
| Ratio | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
Net debt / EBITDA pre-AASB 16 (x) | 2.9 | 2.6 | 2.6 | 2.3 |
Net debt / equity (%) | 52.1 | 60.8 | 42.9 | 43.9 |
Gross borrowings / equity (x) | — | — | 0.49 | 0.50 |
Current ratio (x) | — | — | 0.67 | 0.67 |
ROIC on operating EBIT – company (%) | — | — | 7.3 | 7.6 |
ROE statutory, average equity (%) | — | -18.0 | 0.6 | 3.2 |
ROE operating, average equity (%) | — | 5.4 | 6.4 | 6.9 |
ROA statutory (%) | — | — | — | 1.5 |
Asset turnover (x) | — | — | — | 0.55 |
Operating EBIT / cash interest incl. leases (x) | — | — | 2.4 | 3.5 |
Weighted avg interest rate on core debt (%) | — | — | 6.24 | 5.36 |
Receivable days (days) | — | — | — | 14 |
Region Margins & Growth (%) and Revenue by Region (%)
| Metric (%) | FY24 | FY25 | FY26 |
|---|---|---|---|
Australia organic revenue growth (legacy IDX) | 7.2 | 7.3 | 8.9 |
Australia organic revenue growth (group, all sources) | 7.2 | — | 7.4 |
Medicare benefits growth, comparable reference | 9.7 | — | 9.4 |
New Zealand organic revenue growth (constant currency) | 5.3 | 1.4 | 2.1 |
Australia average fee per exam growth | 7.7 | — | 6.5 |
Medicare indexation applied 1 July | 3.6 | — | 2.4 |
Region Overview
| Region | Clinics | Comprehensive | Share of group clinics (%) |
|---|---|---|---|
Victoria (Metro + Regional + IOP) | 63 | 31 | 44.7 |
Queensland | 40 | 17 | 28.4 |
Western Australia | 12 | 4 | 8.5 |
New Zealand | 19 | 5 | 13.5 |
Tasmania | 5 | 3 | 3.5 |
South Australia | 2 | 2 | 1.4 |
Share Price History
| Date | Price (AUD) | Source |
|---|---|---|
26 Aug 2025 (FY25 result release) | 2.72 | InvestSMART |
14 Jan 2026 | 2.65 | FNArena |
26 Mar 2026 | 2.41 | FNArena |
24 Jun 2026 (Chair purchase) | ~1.96 | Motley Fool insider data |
22–28 Jul 2026 | 2.05–2.08 | Motley Fool price history |
10 Aug 2026 (pre-release) | 2.18 | InvestSMART |
2 Sep 2026 | 2.35 | InvestSMART |
30 Sep 2026 | 2.16 | InvestSMART |
Market Valuation and Per-Share Data
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
Market capitalisation at 30 June (AUD Mn) | 624.7 | 946.0 | 746.1 |
Dividends declared per share (AUD cents) | 5.8 | 6.5 | 9.3 |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
P/E (operating, FY26) | ~17.1x | 216c / 12.6c |
P/E (statutory diluted, FY26) | ~37x | 216c / 5.8c |
EV/EBITDA (pre-AASB 16) | ~8.5x | (805 + 298.9) / 129.6 |
EV/EBITDA (post-AASB 16, incl. leases) | ~8.2x | (805 + 298.9 + 255.4) / 164.8 |
EV/Sales | ~1.4x | (805 + 298.9) / 788.7 |
P/B | ~1.18x | 805 / 681.5 |
Dividend yield (FY26 declared, fully franked) | ~4.3% | 9.3c / 216c |
Per-Share Data
| Metric (AUD cents) | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
Interim dividend | 4.0 | 2.5 | 2.5 | 2.5 | 3.3 |
Final dividend | 3.0 | 3.5 | 3.3 | 4.0 | 6.0 |
Total dividend | 7.0 | 6.0 | 5.8 | 6.5 | 9.3 |
Maturity Year Details
| Maturity year | Committed facilities maturing (AUD Mn) |
|---|---|
FY27–FY29 | 0 |
FY30 (Dec 2029) | 467.4 |
Analyst Conclusions
Management guidance (FY27)
-
Continued revenue growth; operating EBITDA margin improvement to >21.0%.
-
Capex of A$50–60m.
-
Continued de-gearing within a 2.0–2.5x target range.
-
Statutory-to-operating earnings gap expected to narrow significantly beyond FY26.
-
No quantitative revenue or NPAT guidance.
Consensus expectations
Inputs suggest a FY27 baseline of: Medicare indexation 2.6% + volume growth + mix shift (FY26 average fee per exam +6.5%), implying high-single-digit organic revenue growth if Australia tracks recent rates, and margin expansion from a 2H FY26 exit rate of ~21.2% (derived).
Bull case
-
Margin runway is already visible. The 2H FY26 margin of ~21.2% (derived) exceeds the >21% target before FY27's A$-scale procurement savings, 2.6% indexation and new-site ramp-up; every 100 bps of margin on ~A$840m of revenue adds ~A$8m of EBITDA.
-
Integration costs roll off, cash flows to equity. FY26 carried A$19.6m of cash transaction and integration costs; as these fade, A$100m+ of operating FCF should drive genuine de-gearing toward 2.0x and support dividend growth.
-
Regulatory tailwinds stack up. NLCSP spend expected to grow >50% p.a. for three years (IDX's share ~14% vs 12% market share), and full MRI deregulation in July 2027 lets IDX monetise its 62 comprehensive sites.
Bear case
-
Share loss is real. Group Australian organic growth (7.4%) trailed Medicare (9.4%) in FY26; legacy Capitol grew only 5.4%. A larger network growing slower than the market is a strategic problem, not a timing issue.
-
Returns do not cover the merger's cost. ROIC is 7.6% on a goodwill-heavy base (A$846.8m intangibles; negative NTA); statutory ROE is ~3%. Deregulation also arms competitors with MRI capacity in IDX's markets.
-
Execution and leadership risk. A new CEO and CFO arriving within two months, a possible NZ divestment, ongoing system consolidation, and an FY26 EPS outcome (12.6c) below prior broker forecasts (13.3–13.4c) raise the risk of a reset at the AGM or 1H FY27 result.
Catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable | What to watch |
|---|---|---|
| 29 Oct 2026 | AGM | Trading update for 1Q FY27; any quantitative guidance; first public view of Martinez's priorities |
| ~Early Nov 2026 | Completion of CEO 90-day review | Cost-out program, portfolio decisions, technology roadmap |
| Nov 2026 | Employee engagement survey | Culture post-integration and leadership change |
| H2 CY2026 | NZ strategic review | Confirmation, outcome, valuation and use of proceeds |
| Feb 2027 | 1H FY27 results | Margin vs >21%; organic growth vs Medicare; statutory/operating gap; leverage |
| 1 Jul 2027 | Full MRI deregulation | IDX capex plans and competitor MRI announcements |
| Ongoing | Monthly Medicare DI statistics | Market growth vs IDX organic rates |
| Ongoing | IDXt radiologist count and external revenue | Productivity lever |
| Ongoing | Substantial-holder notices | Register stability after WAM/Challenger exits |
Analyst verdict
Integral Diagnostics has completed the hard part of its transformation: the Capitol Health merger is integrated, synergies have beaten the original target by more than 40%, operating EBITDA margin has climbed to 20.9% with a second-half exit rate above 21%, and operating free cash flow now exceeds A$100m a year. The balance sheet, at 2.3x covenant leverage with headroom to 2029, is no longer a constraint, and the regulatory backdrop — indexation of 2.6%, lung cancer screening scaling rapidly, and full MRI deregulation in mid-2027 — is the most supportive the sector has seen in a decade.
The equity story, however, has shifted from "can they integrate?" to "can they grow at or above the market with acceptable returns?". On that question the evidence is mixed. Group Australian organic growth lagged Medicare by two percentage points in FY26, the legacy Capitol network is under-earning, New Zealand remains a low-growth drag that may be divested, and a 7.6% ROIC on a goodwill-laden base means the merger has so far created scale more than value. The simultaneous arrival of a new CEO and CFO adds both opportunity and risk: Jason Martinez brings direct experience of running I-MED's largest regions and has publicly committed to margin, workforce and culture, but strategic resets frequently bring "kitchen-sink" provisions and revised targets.
At roughly 17x operating earnings, ~8.5x pre-AASB 16 EV/EBITDA and a ~4.3% fully franked yield, the valuation embeds limited optimism after a ~16–20% share price decline over the past year, and consistent insider buying near A$2.00 is a supportive signal. Our assessment: constructive but conditional. The investment case strengthens materially if the October AGM and the February 2027 half-year confirm margin above 21%, organic growth converging on Medicare, a clear NZ decision and a visible decline in statutory adjustments. Failure on growth versus market would leave IDX a cash-generative but structurally low-return roll-up.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles | Education |
|---|---|---|---|---|
Jason Martinez | Managing Director & CEO | From 6 Aug 2026 (appointment announced 10 Nov 2025) | EGM NSW, ACT and WA at I-MED Radiology (2015–2025); COO and Executive Director at Konekt (now APM Group); Head of Specialist Services Medical Centres at Healius; Practice Director at Ineum Consulting; Chartered Accountant | BCom, GAICD |
Jenny Martin | Chief Financial Officer | From 5 Oct 2026 | — | — |
Craig White | Outgoing CFO (transition to 31 Oct 2026) | Long-serving; transformed finance, risk and legal functions; also held COO responsibilities for a period (per 10 Aug 2026 release) | — | — |
Dr Ian Kadish | Former MD & CEO (retired 6 Aug 2026) | 22 May 2017 – 6 Aug 2026 | CEO Pulse Health; CEO Healius Pathology; COO Greencross; Netcare executive director; McKinsey | University of the Witwatersrand; MBA, Wharton |
John Merity | Company Secretary | — | — | — |
Chief Medical Officer, Chief Information Officer, Chief People Officer | Executive roles listed in FY26 Annual Report | — | — | — |
“—” = not publicly disclosed.
Board of Directors
| Name | Role | Appointed | Independent | Key experience | Committees | IDX shares |
|---|---|---|---|---|---|---|
Toby Hall | Chair | Director 28 Sep 2023; Chair 29 Nov 2023 | Yes | Group CEO, St Vincent's Health Australia (2014–2022); NED Ingenia Communities, Siloam International Hospitals | Chair Nomination; Audit; PCR | 276,571 |
Jason Martinez | MD & CEO | 6 Aug 2026 | No (executive) | See above | — | Nil |
Andrew Fay | NED | 18 Jul 2022 | Yes | Ex-CEO/CIO Deutsche Asset Management (Australia); Chair Growthpoint Properties Australia | Chair PCR; Audit; Nomination | 85,000 |
Ingrid Player | NED | 29 Aug 2023 | Yes | Former Group Executive Legal, Governance and Sustainability at a major Australian healthcare provider; NED Cleanaway, Cogstate | Chair RCS; Audit; PCR; Nomination | 60,000 |
Laura McBain | NED | 20 Dec 2024 | Yes | Ex-MD Bellamy's Australia, Maggie Beer Holdings; ex-Capitol NED | Chair Audit (from Mar 2026); RCS | 23,250 |
Dr Kevin Shaw | NED | 20 Dec 2024 | Yes | Radiologist; Director of Medical Imaging, Barwon Health; ex-Capitol NED | RCS; PCR | 28,000 |
Dr Manish Mittal | Non-Executive Radiologist Director | 5 Feb 2025 | No (employed radiologist; IDXt Clinical Director) | 18+ years in IDX and predecessor practices; MRI focus | RCS | 2,122,908 |
Major Shareholders
| Holder | Stake (%) | Shares | Date / source |
|---|---|---|---|
Australian Retirement Trust | 5.043 | 18,811,967 | Substantial notice, crossed 29 May 2026 (FilingReader summary) |
The Vanguard Group | 5.124 | 19,051,852 | — |
Challenger Limited (CGF) and associates | Became substantial at 5.40%; later ceased; further change notice 4 Sep 2026 | — | TipRanks; InvestSMART announcements list |
Wilson Asset Management (WAM/WAX/WMI) | Ceased to be substantial 17 Sep 2026 | — | InvestSMART announcements list |
Unnamed new substantial holder | ≥5 | — | "Becoming a substantial holder", 23 Jun 2026 |
Competitive Landscape
Key Competitors
| Competitor | Ownership | Geography | Positioning vs IDX |
|---|---|---|---|
I-MED Radiology Network | Private equity (Permira) | National (Australia) | Largest Australian imaging network; IDX's new CEO came from I-MED |
Sonic Healthcare – Sonic Imaging (incl. Queensland X-Ray and other brands) | Listed (ASX: SHL) | National; overlaps Qld and Vic | Diversified pathology/imaging giant with scale purchasing |
Lumus Imaging | Divested by Healius in 2024 to private equity (Affinity Equity Partners — verify) | NSW, Vic, Qld, WA | Large multi-state competitor |
Qscan Group | Private | Qld, NSW, WA, Vic | Direct competitor in Qld |
Perth Radiological Clinic | Private | WA | Perth metro incumbent |
Envision Medical Imaging / SKG Radiology | Private / group-owned | WA | Perth competitors |
PRP Diagnostic Imaging | Private | NSW | Limited overlap |
Hospital-based public radiology (state health services) | Public | All states | Competes for complex work; also a customer for teleradiology |
Mercy Radiology / Pacific Radiology / Auckland Radiology Group | Private | New Zealand | Auckland competitors; referrer-owned practices hurt IDX NZ |
Everlight Radiology and other teleradiology providers | Private | ANZ / international | Compete with IDXt |
Competitor Detail
| Metric | IDX FY26 |
|---|---|
Revenue (AUD Mn) | 788.7 |
Revenue growth (%) | 25.6 |
Operating EBITDA margin (%) | 20.9 |
Clinics | 142 |
Australian market share (%) | ~12 |



